RecruitingPhase 2NCT07013591

Nicotinamide Mononucleotide in Patients Undergoing Cardiac Surgery

Randomized Clinical Trial of Beta Nicotinamide Mononucleotide in Patients Undergoing Cardiac Surgery


Sponsor

Brigham and Women's Hospital

Enrollment

90 participants

Start Date

Jun 10, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective cardiac surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called MIB-626 and Placebo for people with coronary artery bypass graft. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMIB-626

An orally-administered stable crystalline tablet formulation of NMN

OTHERPlacebo

matching placebo tablets


Locations(1)

Brigham and Women's Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07013591


Related Trials